Cancer Medicines Outcomes Programme Public Health Scotland (CMOP-PHS) report for the Scottish Medicines Consortium (SMC)
First line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC): information for SMC decision SMC2735
A Management Information Statistics publication for Scotland
- Published
- 04 March 2025 (Latest release)
- Type
- Statistical report
- Author
- Public Health Scotland
About this release
This release by Public Health Scotland (PHS) uses information from the National SACT dataset.
This work was requested by the Scottish Medicines Consortium (SMC) to support their decision-making processes.
The aim of this work was to capture real-world evidence from Scotland on the use of first line systemic anti-cancer therapy (SACT) for treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). The information on the use of these treatments in Scotland will assist the SMC members when considering the submission for durvalumab in combination with tremelimumab for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (SMC2735).
It was agreed with SMC members that this pilot report will only provide information on the number of patients treated and their baseline characteristics. No information will be provided on overall survival or subsequent treatments.
General enquiries
If you have an enquiry relating to this publication, please contact Kimberley Philip at phs.cmop@phs.scot.
Media enquiries
If you have a media enquiry relating to this publication, please contact the Communications and Engagement team.
Requesting other formats and reporting issues
If you require publications or documents in other formats, please email phs.otherformats@phs.scot.
To report any issues with a publication, please email phs.generalpublications@phs.scot.
Older versions of this publication
Versions of this publication released before 16 March 2020 may be found on the Data and Intelligence, Health Protection Scotland or Improving Health websites.